Serum Creatine Kinase Levels in Overt and Subclinical Hypothyroidism

Abstract

The aims of this prospective study were to determine serum levels of creatine kinase (CK) in overt and subclinical hypothyroidism; to investigate the change in CK levels with treatment; and to evaluate the relationship between free triiodsothyronine (FT₃), free thyroxine (FT₄), and thyrotropin (TSH) levels and the degree of skeletal muscle involvement, as determined by serum CK levels.

Patients with hypothyroidism presenting to our endocrinology clinic were eligible for inclusion in this study. Patients with other causes of CK elevation were excluded. We included 28 patients (25 women and 3 men, ages 41.75 ± 13.65 years) with overt hypothyroidism, 38 patients (37 women, 1 man, ages 40.55 ± 10.48 years) with subclinical hypothyroidism, and 30 age- and gender-matched controls (27 women, 3 men, ages 40.81 ± 11.20 years) in the study. Serum levels of TSH, FT₄, FT₃, and CK were measured in all subjects.

CK elevation was found in 16 patients (57%) with overt hypothyroidism and in 4 patients (10%) with subclinical hypothyroidism. Although a statistically significant elevation of CK levels was found in patients with overt hypothyroidism when compared with patients with subclinical hypothyroidism and controls (p = 0.0001, p = 0.01, respectively), no difference was found between the subclinical hypothyroidism and control groups (p = 0.14). In hypothyroid (overt and subclinical) patients, a positive correlation was found between CK and TSH (r = 0.432; p = 0.04), and a negative correlation between CK and FT₃ (r = −0.556; p = 0.002) and between CK and FT₄ (r = −0.448; p = 0.04). CK levels decreased to normal levels after thyroid function normalized with treatment.

In conclusion, skeletal muscle is affected by hypothyroidism more profoundly in cases of overt hypothyroidism, less so when subclinical hypothyroidism is present.

Keywords:

• Creatine kinase
• Hypothyroidism
• Subclinical hypothyroidism

ACKNOWLEDGMENT

This study was partially presented in 2003 at the 6th European Congress of Endocrinology, Lyon, France.